Vatukoula Gold Mines
SPECULATIVE BUYVatukoula Gold Mines says it could be producing at an annual rate of 100,000 oz before July 2010, subject to equipment delivery.
Steered by entrepreneurial chief executive officer David Paxton, the AIM-quoted company, which started producing gold at Vatukoula in Fiji last year and lost £3.9m in the six months to February, says the mine increased its output 17% to 8,711 oz of gold in the three months to May.
According to Vatukoula, the mine achieved a net profit of £983,000 over the same period, having lost £742,000 in the previous quarter, helped by a 25% fall in cash costs to $680 an ounce and a 4% increase in the average gold price realised to $920 an ounce – against a current gold price of $933.25 an ounce.
Paxton and his fellow directors now suggest the company could lift gold production to an annual rate of 110,000 oz during the first half of next year, provided present mine refurbishment goes to plan and mobile equipment is delivered to schedule. Vatukoula says it hopes to cut costs by switching equipment from diesel to sugar-based power.
Vatukoula’s shares have veered between 4p and 0.53p over the past 12 months. Ten days ago, the company raised £1.2m by issuing shares at 0.6p to Canadian Zinc, a company headed by Anglesey Mining chairman John Keaerney.
On paper, Canadian Zinc has already more than doubled its money, with Vatukoula shares now trading at 1.1p. There is a significant risk in an entrepreneurial venture like this, especially in today’s markets, but, if the equipment arrives in time, gold stays firm and Paxton’s production targets are met, it might in time reward a bold punt.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £30m
PE Forecast: n/a
Share price: 110p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
